| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| ImmunityBio, Inc. | Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | Common Stock | 32,606,985 | $111,515,889 | $3.42 | 22 Feb 2025 | Indirect |
| ImmunityBio, Inc. | Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | Common Stock | 29,546,190 | $101,047,970 | $3.42 | 22 Feb 2025 | Direct |
| NantHealth, Inc. | Chief Executive Officer, Director, 10%+ Owner | Common Stock | 15,921,888 | $31,219,638 | $1.96 | 28 Aug 2023 | Indirect |
| ImmunityBio, Inc. | Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | Common Stock | 7,976,159 | $27,278,464 | $3.42 | 22 Feb 2025 | See footnte |
| ImmunityBio, Inc. | Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | Restricted Stock Units | 228,658 | $782,010 | $3.42 | 22 Feb 2025 | Direct |
| ImmunityBio, Inc. | Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | Stock Option (right to buy) | 2,812,500 | 10 Feb 2025 | Direct | ||
| ImmunityBio, Inc. | Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | Amended and Restated Promissory Note | $0 | 10 Dec 2024 | Indirect | ||
| ImmunityBio, Inc. | Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | Convertible Promissory Note | $0 | 10 Dec 2024 | Indirect | ||
| ImmunityBio, Inc. | Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | Second Amended and Restated Convertible Promissory Note | $505,000,000 | 10 Dec 2024 | Indirect |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| IBRX | ImmunityBio, Inc. | 22 Feb 2025 | 3 | -$143,883 | 4 | Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | 25 Feb 2025, 21:11 |
| IBRX | ImmunityBio, Inc. | 10 Feb 2025 | 2 | $0 | 4 | Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | 12 Feb 2025, 20:17 |
| IBRX | ImmunityBio, Inc. | 10 Dec 2024 | 6 | +$126,402,412 | 4 | Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | 12 Dec 2024, 21:20 |
| IBRX | ImmunityBio, Inc. | 22 Feb 2024 | 2 | $0 | 4 | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | 26 Feb 2024, 16:36 |
| IBRX | ImmunityBio, Inc. | 29 Dec 2023 | 2 | +$410,000,000 | 4 | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | 03 Jan 2024, 21:53 |
| IBRX | ImmunityBio, Inc. | 11 Sep 2023 | 9 | +$199,999,997 | 4 | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | 13 Sep 2023, 21:07 |
| NHIQ | NantHealth, Inc. | 28 Aug 2023 | 2 | +$15,999,975 | 4 | Chief Executive Officer, Director, 10%+ Owner | 30 Aug 2023, 17:26 |
| IBRX | ImmunityBio, Inc. | 12 May 2023 | 1 | +$30,455,859 | 4 | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | 16 May 2023, 20:30 |
| IBRX | ImmunityBio, Inc. | 12 Dec 2022 | 2 | -$5.11 | 4 | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | 14 Dec 2022, 15:23 |
| IBRX | ImmunityBio, Inc. | 31 Aug 2022 | 6 | +$315,096,248 | 4 | Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner | 08 Nov 2022, 15:01 |
| IBRX | ImmunityBio, Inc. | 23 Mar 2022 | 2 | $0 | 4 | Executive Chairman, Director, 10%+ Owner | 25 Mar 2022, 21:05 |
| NHIQ | NantHealth, Inc. | 09 Sep 2021 | 1 | $0 | 4 | Chairman and CEO, Director, 10%+ Owner | 13 Sep 2021, 20:19 |
| IBRX | ImmunityBio, Inc. | 10 Jun 2021 | 1 | $0 | 4 | Executive Chairman, Director, 10%+ Owner | 14 Jun 2021, 18:38 |